Answers are grounded in this paper and cite their sources.
Reimbursement review evaluates clinical and cost-effectiveness of trabectedin with doxorubicin for advanced leiomyosarcoma, informing treatment guidelines.
Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec. This review assesses trabectedin, 1 mg per vial, sterile lyophilized powder for IV injection through a central line. Indication: Trabectedin in combination with doxorubicin for the first-line treatment of advanced unresectable or metastatic uterine or soft tissue leiomyosarcoma in adults.
No takes yet. Share an insight, caveat, or question.
CDA-AMC (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: